New-onset cardiovascular risk factors in lung transplant recipients
- PMID: 16210127
- DOI: 10.1016/j.healun.2005.01.004
New-onset cardiovascular risk factors in lung transplant recipients
Abstract
Background: Cardiovascular disease (CVD) is a common cause of morbidity and mortality after solid-organ transplantation. Both pre-existing cardiovascular risk factors in recipients and immunosuppressive drug toxicity may contribute to CVD. We sought to describe the prevalence of new-onset hypertension, hypercholesterolemia and diabetes mellitus in lung transplant recipients and to identify predisposing factors.
Methods: One hundred twenty-six patients without pre-transplant hypertension, hypercholesterolemia or diabetes were included in a retrospective descriptive study. All patients were initially on cyclosporine-based triple immunosuppression. Cumulative prevalence of new-onset hypertension, hypercholesterolemia and diabetes were calculated. A multivariate Cox regression model was used to identify independent pre-operative predictors.
Results: By 3 years after transplantation, 90% of patients had developed at least 1 cardiovascular risk factor and 40% developed > or = 2 risk factors. The cumulative prevalence of new-onset hypertension at 1, 3, 5 and 7 years was 45%, 65%, 67% and 72%, respectively. The corresponding prevalence for hypercholesterolemia was 16%, 33%, 48% and 58%, and for diabetes 6%, 7%, 7% and 10%, respectively. The independent pre-transplant predictors were: for hypertension, diastolic blood pressure (odds ratio: 2.1 per 10 mm Hg [95% confidence interval: 1.3 to 3.5], p = 0.005); for hypercholesterolemia, serum cholesterol level (OR: 1.8 per mmol/liter [95% CI: 1.3 to 2.5], p < 0.001); and, for diabetes, cystic fibrosis diagnosis (OR: 7.4 [95% CI: 1.6 to 35.6], p = 0.01) and blood glucose level (OR 2.2 per mmol/liter [95% CI 1.1 to 4.5], p = 0.02).
Conclusions: The majority of cyclosporine-treated lung transplant recipients develop new-onset hypertension or hypercholesterolemia early after transplantation. Pre-transplant blood pressure, serum cholesterol levels and blood glucose levels are independent predictors of post-transplant hypertension, hypercholesterolemia and diabetes, respectively.
Similar articles
-
New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.J Heart Lung Transplant. 1997 Mar;16(3):275-82. J Heart Lung Transplant. 1997. PMID: 9087870
-
Ischemic heart disease after renal transplantation in patients on cyclosporine in Spain.J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S286-90. doi: 10.1681/ASN.2006080928. J Am Soc Nephrol. 2006. PMID: 17130276
-
A long-term study on hyperlipidemia in stable renal transplant recipients.Clin Transplant. 2004 Jun;18(3):274-80. doi: 10.1111/j.1399-0012.2004.00160.x. Clin Transplant. 2004. PMID: 15142048
-
New-onset diabetes after transplantation.J Heart Lung Transplant. 2004 May;23(5 Suppl):S194-201. doi: 10.1016/j.healun.2004.03.007. J Heart Lung Transplant. 2004. PMID: 15093805 Review.
-
Risk profile for cardiovascular morbidity and mortality after lung transplantation.Nurs Clin North Am. 2008 Mar;43(1):37-53; vi. doi: 10.1016/j.cnur.2007.10.002. Nurs Clin North Am. 2008. PMID: 18249224 Review.
Cited by
-
The Evaluation and Management of Coronary Artery Disease in the Lung Transplant Patient.J Clin Med. 2023 Dec 13;12(24):7644. doi: 10.3390/jcm12247644. J Clin Med. 2023. PMID: 38137713 Free PMC article. Review.
-
The prevalence of vascular and metabolic complications after lung transplant in people with cystic fibrosis in a Dutch cohort.Clinics (Sao Paulo). 2023 Aug 17;78:100274. doi: 10.1016/j.clinsp.2023.100274. eCollection 2023. Clinics (Sao Paulo). 2023. PMID: 37597473 Free PMC article.
-
Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination.Transpl Int. 2023 Jan 20;36:10704. doi: 10.3389/ti.2023.10704. eCollection 2023. Transpl Int. 2023. PMID: 36744051 Free PMC article.
-
Drug treatment of cystic fibrosis.Aust Prescr. 2022 Oct;45(5):171-175. doi: 10.18773/austprescr.2022.063. Epub 2022 Oct 4. Aust Prescr. 2022. PMID: 36382177 Free PMC article. Review.
-
Non-pulmonary complications after lung transplantation: Part I.Indian J Thorac Cardiovasc Surg. 2022 Jul;38(Suppl 2):280-289. doi: 10.1007/s12055-021-01223-z. Epub 2021 Oct 8. Indian J Thorac Cardiovasc Surg. 2022. PMID: 35756951 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical